MX2012003007A - Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. - Google Patents

Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.

Info

Publication number
MX2012003007A
MX2012003007A MX2012003007A MX2012003007A MX2012003007A MX 2012003007 A MX2012003007 A MX 2012003007A MX 2012003007 A MX2012003007 A MX 2012003007A MX 2012003007 A MX2012003007 A MX 2012003007A MX 2012003007 A MX2012003007 A MX 2012003007A
Authority
MX
Mexico
Prior art keywords
bcl
family proteins
sulfonamides
inhibitors
cancer
Prior art date
Application number
MX2012003007A
Other languages
English (en)
Spanish (es)
Inventor
Naeem Yusuff
Karen Miller-Moslin
Bakary-Barry Toure
Michael Scott Visser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012003007A publication Critical patent/MX2012003007A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2012003007A 2009-09-10 2010-09-08 Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. MX2012003007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24125109P 2009-09-10 2009-09-10
PCT/EP2010/063169 WO2011029842A1 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2012003007A true MX2012003007A (es) 2012-04-11

Family

ID=43016684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003007A MX2012003007A (es) 2009-09-10 2010-09-08 Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.

Country Status (12)

Country Link
US (1) US8809352B2 (https=)
EP (1) EP2475661B1 (https=)
JP (1) JP2013504536A (https=)
KR (1) KR20120078715A (https=)
CN (1) CN102498111A (https=)
AU (1) AU2010294292B2 (https=)
BR (1) BR112012005343A2 (https=)
CA (1) CA2772989A1 (https=)
EA (1) EA020586B1 (https=)
ES (1) ES2443845T3 (https=)
MX (1) MX2012003007A (https=)
WO (1) WO2011029842A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192126A1 (en) * 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
EP2794588A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503518A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
JP6223563B2 (ja) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10975051B2 (en) * 2015-08-12 2021-04-13 Memorial Sloan Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
WO2017123616A1 (en) * 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins
SI3788042T1 (sl) 2018-04-29 2025-06-30 Beigene Switzerland Gmbh Zaviralci BCL-2
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
JP7839962B2 (ja) 2020-04-15 2026-04-03 ビーワン メディシンズ ワン ゲーエムベーハー Bcl-2阻害剤
EP4538273A1 (en) * 2022-06-10 2025-04-16 Hitgen Inc. Compound and use thereof in preparation of bcl-xl inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1487811B1 (en) * 2002-03-21 2007-09-05 Abbott Laboratories N-sulfonylurea apoptosis promoters
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
EP1778206A4 (en) * 2004-08-20 2009-08-05 Univ Michigan SMALL MOLECULE INHIBITORS FROM MEMBERS OF THE ANTIOPTOTIC BCL-2 FAMILY AND USES THEREOF
EP2094672B1 (en) * 2006-11-15 2013-05-29 Genentech, Inc. Arylsulfonamide compounds
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EA201200472A1 (ru) 2012-10-30
KR20120078715A (ko) 2012-07-10
EA020586B1 (ru) 2014-12-30
WO2011029842A1 (en) 2011-03-17
EP2475661B1 (en) 2013-10-23
AU2010294292A1 (en) 2012-03-01
AU2010294292B2 (en) 2013-07-18
CN102498111A (zh) 2012-06-13
US8809352B2 (en) 2014-08-19
BR112012005343A2 (pt) 2016-03-22
US20120165298A1 (en) 2012-06-28
EP2475661A1 (en) 2012-07-18
CA2772989A1 (en) 2011-03-17
JP2013504536A (ja) 2013-02-07
ES2443845T3 (es) 2014-02-20

Similar Documents

Publication Publication Date Title
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX2011009796A (es) Inhibidores de la cinasa pi3.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2013012588A (es) Inhibidores de cinasa.
WO2009155121A3 (en) Inhibitors of pi3 kinase
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
MX362550B (es) Inhibidores ciclicos de glutaminasa.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
TN2012000248A1 (en) Novel spiropiperidine compounds
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
TW200745066A (en) Novel PTP1B inhibitors
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
FG Grant or registration